Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

SGMTBullishIndustry Newsnews

High materiality7/10

Sagimet reports positive acne data as US AURORA trial targets October 2026 kickoff

Sep 30, 2026, 6:06 AM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Strong Phase 3 extension data supports long-term value; US trial kickoff adds near-term catalysts; limited safety concerns reduce dilution risk, though no FDA decision yet.

AI summary

What happened, with direct paths to the underlying reporting

Sagimet announced positive 52-week ASC40-304 open-label extension results for denifanstat in acne, showing durable efficacy with 57% IGA success and around 72% total lesion reduction. Safety remained favorable with no drug-related discontinuations, though mild dryness-related AEs occurred. The U.S. AURORA Phase 3 trial screening begins October 2026, signaling near-term catalysts and potential first-in-class oral acne therapy if approved.

52-week ASC40-304 open-label extension shows durable acne results.
IGA success 57%; total lesions -72%; inflammatory lesions -77%.
No drug-related discontinuations; dry skin 7.1%, dry eye 5.9%.
U.S. AURORA Phase 3 screening starts October 2026.
KOL event Sept 30, 2026; potential U.S. market opportunity.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

Sagimet reports positive acne data as US AURORA trial targets October 2026 kickoff

Sagimet Announces $175 Million Stock Offering to Fund Clinical Trials